Thu, Jul 2, 2:00 PM, Zacks
Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog
Exelixis Inc.'s (EXEL) announced that the FDA is extending the review period for the new drug application for skin cancer candidate, cobimetinib by three months.
Tue, Jun 30, 2:50 PM, Zacks
Celldex's Rintega Phase III Study Recommended to Continue - Analyst Blog
Celldex Therapeutics (CLDX) announced that the independent Data Safety and Monitoring Board recommended the continuation of a phase III study on Rintega.